Skip to content

A multicenter,prospective,randomized,controlled study of the comprison of resection and radiofrequency ablation for recurrent hepatocellular carcinoma with no greater than 3cm

A multicenter,prospective,randomized,controlled study of the comprison of resection and radiofrequency ablation for recurrent hepatocellular carcinoma with no greater than 3cm

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800015084
Enrollment
Unknown
Registered
2018-03-06
Start date
2018-04-01
Completion date
Unknown
Last updated
2018-03-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hepatitis B virus–related hepatocellular carcinoma

Interventions

Sponsors

West China Hospital, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. older than 18 years and less than 69 years old; 2. the first operation was in accordance with the Milan standard, the treatment was excised, and pathological biopsy is proved to be HCC; 3. at least 2 imaging examinations supported the typical imaging findings of hepatocellular carcinoma, or 1 imaging examinations with AFP > 400 g/L, or cytological and histological evidences prove to be HCC when recurrence; 4. for single tumor recurrence, tumor maximum diameter is less than 3cm; and the resection and radiofrequency ablation both can be implemented; 5. the residual liver volume was still sufficient after resection; 6. ICG-R15<20%; 7. the liver function is Chid-Pugh A, or Child-Pugh B which can return to Class A after treatment; 8. no other major organ dysfunction; 9. patients agreed to participate in the clinical trial.

Exclusion criteria

Exclusion criteria: 1. The image found extrahepatic lymph nodes or visceral metastasis, the existence of large vascular invasion, the existence of bile duct embolus in the first operation; 2. The patient combined with a malignant tumor of other organs or had a history of other malignant tumors in other organs; 3. Liver function decompensation, such as: upper gastrointestinal bleeding, refractory ascites, coagulation dysfunction and so on; 4. contraindications to surgery; 5. Patients with poor compliance and not adhered to the follow-ups; 6. Patients refused to participate in the clinical trial.

Design outcomes

Primary

MeasureTime frame
Routine blood test;Biochemical routine;AFP;PIVKA-II;CEA;Abdominal ultrasound;

Countries

China

Contacts

Public ContactWen Tianfu

West China Hospital, Sichuan University

wentianfu@scu.edu.cn+86 18980601471

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026